Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology
Kancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into an agreement with the Nordic Society of Gynaecological Oncology Clinical Trials Unit (NSGO-CTU).
Kancera has previously announced the decision to proceed into clinical development of its Fractalkine axis blocker KAND567 in ovarian cancer. Women with ovarian cancer are often diagnosed at a late stage and as a consequence, the probability of long-term survival (over 5 years) is greatly reduced. The current standard of care for advanced ovarian cancer is platinum-based chemotherapy. However, the treatment has limitations, as cancer cells develop resistance to chemotherapy over time, through the ability to repair the DNA damage that chemotherapy causes. Kancera’s planned study is a combined phase Ib/IIa study of the study-drug KAND567 in combination with platinum therapy in ovarian cancer patients with relapsed disease. The aim of the combination treatment is to restore sensitivity to platinum treatment and ultimately prolong survival.
The study is planned to be conducted at academic hospitals in Sweden, Denmark and Norway. Kancera has now submitted the first regulatory application to the Swedish Medical Products Agency and applications in Denmark and Norway are planned to follow in Q1 2023. Kancera is convinced that a collaboration with NSGO-CTU will strengthen the study, both in terms of quality and effectiveness.; NSGO is a Nordic Society among the leading academic hospitals and gynaecological clinicians in the Nordic countries. The organization aims to set Nordic Standards of treatment and care for women with gynaecological cancers. Through the Clinical Trial Unit NSGO sponsors, develops and conducts collaborative clinical trials within the field of gynaecological malignancies.
”In collaboration with NSGO, we will be able to effectively advance Kancera’s new class of cancer drug into a pioneering pan-Nordic phase clinical study addressing significant medical needs. NSGO-CTU has provided key scientific advice on the study design and been instrumental in building a team of leading clinicians in the field to conduct the study”, says Thomas Olin, CEO of Kancera.
“Women with far progressed ovarian cancer that experience relapse from platinum chemotherapy have very few treatment options left. The opportunity for KAND567 to restore platinum sensitivity is, even though at an early stage, very interesting. We are very enthusiastic about the opportunity to support a Nordic biotech to potentially develop a new treatment option for these patients.”, says Dr. Mansoor Raza Mirza, Medical Director and head of the NSGO-CTU.
About Kancera AB (publ)
Kancera is developing a new class of drugs for treatment of cancer and severe inflammatory diseases, that today are lacking effective treatments. Kancera’s main focus is to develop small molecule drug candidates based on the Fractalkine system. Fractalkine is a natural master regulator that with precision controls immune cells and cancer cells. The stock is traded on the Nasdaq First North Premier Growth Market.
For further information:
Chief Executive Officer, Kancera AB
Tel: +46-73-620 40 01
Visit Kancera’s web page: https://www.kancera.com/en
Visit NSGO and NSGO-CTU’s web page: https://nsgo.org